Day-wise ASCO 2024 Summary
Day 1
-
Subcutaneous RYBREVANT data soaring high with unexpectedly better performance than its Intravenous version
-
Post failure of Gilead’s Trodelvy in confirmatory bladder cancer trial, the ADC has bad news in NSCLC, although it shows survival benefits to non-responders to PD-(L)1 blockade
-
With the planned submission of SCEMBLIX in 2024 for 1L CML, the Phase III ASC4FIRST trial meets both primary endpoints with clinically meaningful and statistically significant results
-
Summit’s lead bispecific (PD-1 X VEGF) data beats Merck’s Keytruda. Company Stocks jump after HARMONi-A trial findings released for EGFR-mutant non-squamous non-small cell lung cancer
-
Johnson & Johnson broadening RYBREVANT’s label, now moving towards EGFR exon 19 deletions or L858R mutations in first-line NSCLC
-
Merck and Kelun’s new TROP-2 ADC, Sacituzumab Tirumotecan (SKB264/MK-2870) shines in advanced NSCLC in Phase II trial
-
Non-squamous histology in NSCLC, appears to derive the greatest benefit with Dato-DXd, data from the ICARUS-LUNG01 study revealed
-
China-based Curon Biopharma’s bispecific CN201, a Next Generation CD3 × CD19 T-cell Engager, reports the longest duration of response of 8 months in R/R B-cell ALL patients
-
Post KYMRIAH and YESCARTA, Autolus’ CD-19 CAR-T, Obe-cel is expected to receive approval in R/R B-cell ALL patients
-
Novartis planning to strengthen its portfolio with Pelabresib and JAKAFI Combo, a Breakthrough in reducing Splenomegaly for JAK Inhibitor naive Patients
Day 2
-
Fulzerasib emerges as a game-changer for KRAS G12C-mutated NSCLC with promising preliminary efficacy and an excellent safety profile in Phase II KROCUS Study!
-
Adagrasib shines in KRYSTAL-12 trial in confirmatory trial: Will the FDA be convinced despite Progression-Free Survival Debate?
-
Lilly’s Verzenio is expected to be a promising option in HR+, HER2- advanced breast cancer patients after disease progression on a CDK4/6 inhibitor, regardless of biomarker status
-
Sigvotatug Vedotin, Pfizer's Most Anticipated Antibody Drug Conjugate (ADC) in NSCLC Treatment - Updated Phase I Insights Unveiled
-
Data from Pivotal Phase II TRUST-I study of taletrectinib, a ROS1 inhibitor: One of the largest trials to date among people with ROS1-positive NSCLC!
-
Sunvozertinib: Shanghai-based biopharmaceutical company, Dizal Paving the Global Path for EGFR Exon 20 Insertion Mutation Treatment
-
The addition of CDK4/6 inhibitor, VERZENIO to ZYTIGA did not significantly improve rPFS in mCRPC patients, Lilly presents data from CYCLONE 2 trial
-
Cantargia's Nadunolimab, dual Benefits in Pancreatic Ductal Adenocarcinoma (PDAC) Treatment - Antitumor Efficacy and Neuropathy Reduction – CANFOUR Study
-
FutureGen’s CLDN18.2 inhibitor, FG-M108 Achieves 100% Disease Control in Advanced Pancreatic Cancer
-
Merck’s First-in-Class ILT3 Targeted Therapy Shows Promising Phase I Results in Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
-
Alligator Bioscience’s CD40 inhibitor, Mitazalimab Shows Promising Results in OPTIMIZE-1 Trial for Pancreatic Cancer, Paving the Way for Phase III Development
-
ENHERTU Gains Momentum due to Tumor Agnostic Label in HER2+ solid Tumors. How well are the outcomes in Biliary Tract and Pancreatic Cancer patients?
-
Compugen presents encouraging preliminary results from COM701, a triple combination in microsatellite stable colorectal cancer with liver metastases
-
PolyPEPI1018, an off-the-shelf peptide immunotherapy by Treos Bio, was well-tolerated in its Phase II study of late-stage microsatellite stable metastatic colorectal cancer patients
-
Promising efficacy of Innovent Biologics’ PD-1/IL-2 bispecific antibody fusion protein, IBI363 observed in advanced CRC patients, particularly in PD-L1 CPS ≥1
-
Agenus’ Botensilimab/Balstilimab combo breakthrough data is out for relapsed/refractory metastatic colorectal cancer (mCRC) patients
-
Cue Biopharma’s T-cell engager CUE-102 shows favorable data in HLA-A*0201-positive disease and WT1-positive recurrent/metastatic cancers
-
Post blockbuster IBRANCE’s success, Pfizer is now having hopes for its next-generation CDK4-selective inhibitor, in HR+ HER2- breast cancer patients
-
Encouraging activity in heavily pretreated patients with advanced colorectal cancer by Merck’s first-in-class anti-CEACAM5 ADC with topoisomerase 1 inhibitor payload, M9140
-
Post Enhertu’s recent achievement after gaining a tumor agnostic label in previously treated HER2+ solid tumors, the HER2-ADC is now moving upwards for first-line HER2+ metastatic breast cancer
-
Pfizer and Astellas’ Nectin-4 ADC, Padcev being evaluated in triple-negative breast cancer (TNBC) and HR+/HER2- breast cancer cohorts of the EV-202 trial
-
Exciting news for Roche’s PIKCA-mutated, Inavolisib in HR+HER2 metastatic Breast Cancer patients as it yields better results than Novartis’ PIQRAY
Day 3
-
Mainz Biomed unveils consolidated findings from both ColoFuture and eAArly DETECT study. 92% sensitivity for Colorectal Cancer seems remarkable
-
Natera’s latest results from the CIRCULATE-Japan GALAXY study, showcasing the prognostic and predictive value of Signatera and actionable biomarkers in colorectal cancer
-
LabCorp's validation study of Labcorp Plasma Complete test provides highly specific and accurate detection in advanced stage cancers
- Precede Biosciences' assay determines HER2 status in multiple cancer types with HER2 protein as a hallmark biomarker
-
Interim data readout from Guardant’s RADIOHEAD study, to identify genomic and epigenomic biomarkers using Guardant Infinity in more than 13 cancer types
-
GRAIL’s Multi Cancer Early Detection test (MCED) detects aggressive cancers with high specificity, whereas early-stage cancer can get skipped in the PATHFINDER study
-
HER2 low breast cancer seems to be an evolving space. Eisai presented the most recent findings on BB-1701's anti-HER2 activity in low HER2 expressing breast cancer type
-
Blueprint’s BLU-222, a promising CDK2 inhibitor, demonstrates potential in HR+/HER2- breast cancer
-
Merck & Kelun’s TROP-2 ADC could be a ray of hope post Phase III data readout highlighting its efficacy in the most aggressive breast cancer type, TNBC
Day 4
-
Bayer’s BAY2927088 demonstrates exceptional performance as a novel TKI for HER2-Mutant NSCLC
-
Exact Sciences evaluated the potential impact of MCED screening on Stage IV cancer incidence for 12 cancers that represent 70% of all cancer incidence in the US
-
A saliva-based test that could transform the way prostate cancer is diagnosed, findings from BARCODE 1 study
-
Shanghai's latest Phase Ib/II results reveal promising objective response rate and a well-managed safety profile in Extensive Stage-Small Cell Lung Cancer (ES-SCLC) patients
-
While major players emphasize MRD detection in Advanced cancers, Foresight Diagnostics focuses on early-stage NSCLC patients within the post-operative adjuvant setting
-
FDA Lifts partial hold on Innate Pharma’s lacutamab program, reveals positive clinical activity for mycosis fungoides regardless of KIR3DL2 expression
-
Seagen’s ADCETRIS might be a promising treatment for PTCL patients with less than 10% CD30 expression
-
Chinese player evaluating PI3Kα/δ inhibitor, TQ-B3525 in heavily pretreated relapsed/refractory follicular lymphoma
-
Caribou Biosciences’ Allogeneic CAR-T Therapy, CB-010, demonstrates promising results in relapsed/refractory B-NHL (r/r B-NHL) patients
-
Merus' Petosemtamab is emerging as a potential best-in-class option for first-line HNSCC treatment
-
Mercy BioAnalytics highlighted the performance of its Mercy Halo Ovarian Cancer screening test in a large cohort of asymptomatic, postmenopausal women
-
Exciting Breakthrough for Arvinas’ Novel PROTAC Androgen Receptor, ARV-766, expected to be the first of its kind in metastatic castration-resistant prostate cancer (mCRPC)
-
Spanish player, Amadix presented performance data of PreveCol test for colorectal cancer screening
-
BillionToOne’s already launched assay, Northstar Select has come out favorably in a head-to-head comparison with commercially available assays
-
Adela’s tissue-agnostic MRD assay’s performance for recurrence prediction in patients with head and neck cancer. All set to commercialize the test for clinical use in 2025
-
Personalis NeXT Personal test has shown exceptional ability in identifying molecular residual disease and predicting relapse in early-stage breast cancer
